ConductScience.org, home

Paper40201702

Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.

Salahi-Niri A and 7 others. Health Sci Rep, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review. Papers, record 40201702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40201702

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.
PubMed
Journal
Health Sci Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-04-29
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Salahi-Niri AAryanhttps://orcid.org/0000-0002-6772-0972
2Zarand PPanizhttps://orcid.org/0000-0002-0643-4059
3Shojaeian FFatemehhttps://orcid.org/0000-0001-5972-9953
4Mansouri NNegar
5Yazdani OOmid
6Esbati RRomina
7Safavi-Naini SAASeyed Amir Ahmadhttps://orcid.org/0000-0001-9295-9283
8Jahanbin BBehnazhttps://orcid.org/0000-0002-2762-5591

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References77

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135282081Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study.Ann Transl Med2022https://conductscience.org/library/papers/35282081PubMed
222081974Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.BMC Cancer2011https://conductscience.org/library/papers/22081974PubMed
323672632Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.Curr Med Res Opin2013https://conductscience.org/library/papers/23672632PubMed
420837693A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.Clin Cancer Res2010https://conductscience.org/library/papers/20837693PubMed
526074397
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Eur J Cancer2015https://conductscience.org/library/papers/26074397PubMed
633369635Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.J Natl Cancer Inst2021https://conductscience.org/library/papers/33369635PubMed
723229269Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors.Med Oral Patol Oral Cir Bucal2013https://conductscience.org/library/papers/23229269PubMed
831754747Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.Cancer Chemother Pharmacol2020https://conductscience.org/library/papers/31754747PubMed
924205370The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.PLoS One2013https://conductscience.org/library/papers/24205370PubMed
1016101384The MCM complex: its role in DNA replication and implications for cancer therapy.Curr Cancer Drug Targets2005https://conductscience.org/library/papers/16101384PubMed
1125628920Prognostic significance of minichromosome maintenance proteins in breast cancer.Am J Cancer Res2015https://conductscience.org/library/papers/25628920PubMed
1227756439Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.Breast Cancer Res2016https://conductscience.org/library/papers/27756439PubMed
1325400769Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.Int J Clin Exp Pathol2014https://conductscience.org/library/papers/25400769PubMed
1428075166The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Future Oncol2017https://conductscience.org/library/papers/28075166PubMed
1529693354Proliferative Index (Ki67) for Prediction in Breast Duct CarcinomasAsian Pac J Cancer Prev2018https://conductscience.org/library/papers/29693354PubMed
1617954709American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol2007https://conductscience.org/library/papers/17954709PubMed
1735958459The neoadjuvant chemotherapy responses and survival rates of patients with different molecular subtypes of breast cancer.Am J Transl Res2022https://conductscience.org/library/papers/35958459PubMed
1821555689
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
J Clin Oncol2011https://conductscience.org/library/papers/21555689PubMed
1926205655Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.BMC Cancer2015https://conductscience.org/library/papers/26205655PubMed
2023917950Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.Ann Oncol2013https://conductscience.org/library/papers/23917950PubMed

See all 77 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42923317Immunohistochemical Expression of Proliferating Cell Nuclear Antigen in Invasive Breast Carcinoma: Associations With Histological Grade and Ki-67 Expression.Cureus2026https://conductscience.org/library/papers/42923317PubMed
42530698Emerging biomarkers in breast fibroadenoma: implications for differential diagnosis, malignant transformation, and precision medicine.Mol Biol Rep2026https://conductscience.org/library/papers/42530698PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PCNA5111PubTator's text mininghttps://conductscience.org/library/genes/5111

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40201702

GET https://conductscience.org/api/papers/v1/40201702/references?page=2